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Abstract
Extracellular vesicles (EVs) represent a generic term for all the secreted vesicles, 
which include exosomes, microvesicles, and apoptotic bodies. EVs are key partners 
in the intercellular communication and play an essential role in multiple physi-
ological and pathological conditions. EVs are shuttles for cargo molecules, such as 
RNA (mRNA, microRNA, and other noncoding RNAs), DNA, proteins (receptors, 
transcription factors, enzymes, and extracellular matrix proteins), and lipids. In 
pathological states, including cancer, EVs might represent either useful biomarkers 
or can be used for therapeutic purposes. Moreover, in cancer, it was demonstrated 
that EVs play an essential role in drug resistance. Here, we review the role played by 
EVs in the most common forms of cancer, with a special focus on ovarian and breast 
cancers.
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1. Introduction
Extracellular vesicles (EVs) are cell-derived membranous vesicles (from normal 
or cancerous cells) bearing packages of information within or on their surface. 
Their content can influence neighboring or remote cells, and therefore, EVs are 
considered to play an important role in intercellular communication [1]. Different 
functional molecules (proteins, mRNA, and microRNAs) are transferred between 
cells with the aid of EVs. The content of EVs is highly variable and dependent of 
the cell of origin. The EVs in human blood originate from platelets, leukocytes, 
erythrocytes, endothelial cells, vascular smooth muscle cells, and cancer cells (for 
review see [2]). It is now widely accepted that extracellular vesicles also represent a 
potential resource for biomarkers.
The first study suggesting the existence of extracellular vesicles was carried 
out in 1946 [3]. In a 1967 report, membrane particles derived from activated 
platelets, termed “platelet dust,” were commonly considered as a waste product or 
cellular debris directly budded from the plasma membrane [4]. Both prokaryotes 
and higher eukaryotes can release EVs. Different terms are used to describe EVs 
due to varying methods of isolation and due to the biogenesis mechanism. The 
terminologies of EVs include microvesicles, dexosomes, texosomes, archaeosomes, 
argosomes, prostasomes, epididymosomes, and oncosomes [5]. Gradually, while 
building up knowledge about EVs, a need for its classification emerged and the 
International Society for Extracellular Vesicles (ISEV) was founded [6]. This society 
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provided some criteria to classify EVs into three groups: microvesicles (MVs), 
exosomes, and apoptotic bodies (for details visit www.isev.org). These vesicles are 
secreted by both normal cells and cancerous cells as means of cell-to-cell communi-
cation. Alternatively, they may be prepared artificially from the engineered artifi-
cial lipid vesicles called liposomes in which EVs’ features, components, or cargos are 
incorporated and are the most likely to be useful for drug delivery [7].
EVs are actively involved in cell-to-cell communication, inflammation, chronic 
disease development and progression, pre-metastatic niche formation, and the 
metastatic organotropism of different tumor types [8]. Tumor-derived EVs (TEVs) 
have been reported to play major roles in the onset, progression, and metastasis of 
cancer, including ovarian [9], breast [10], colorectal [11, 12], prostate cancer [13], 
and melanoma [14–16].
Here, we review knowledge about EVs in cancer, with a focus on breast and ovar-
ian cancers. We discuss the importance of the content of EVs (e.g., nucleic acids, 
and proteins) in cancer development, metastasis, and drug resistance.
2. The variety of extracellular vesicles
Replacing EVs includes a heterogeneous population of membrane vesicles 
categorized depending on the mechanism by which they are released from cells. 
According to their size and mechanisms of biogenesis, EVs can be categorized 
into three classes: (a) exosomes, (b) ectosomes or shedding microvesicles, and (c) 
apoptotic bodies [17, 18]. Differentiation criteria are based on their size, content, 
and by a certain combination of markers (Figure 1 and Table 1). Cancerous cells 
have been described to release exosomes and ectosomes and some other additional 
subpopulations of EVs [19].
2.1 Exosomes
Exosomes are EVs with multivesicular endosomal origin released by all cell 
types [33]. Exosomes are found in physiological fluids such as blood and plasma 
[34, 35], urine [36], cerebral fluid [37], saliva [38, 39], seminal fluid [40], breast 
milk [41, 42], and amniotic fluid [43, 44]. The presence of EVs has been reported 
in interstitial spaces since they are released by B cells [45], T cells [46], dendritic 
cells [47], platelets [48], Schwann cells [49], tumor cells [50], cardiomyocytes [51], 
endothelial cells [52], stem cells [50], and telocytes [53–55]. Exosomes are able to 
influence cells from the local environment and also distant target cells, thus regulat-
ing intercellular signaling [56]. Their size varies between 30 and 100 nm, and as 
membrane vesicles, they are delineated by a specific lipid bilayer similar to that of 
the cells they originate from [57]. Studies have shown that while normal human 
blood contains about 2000 trillion exosomes, the blood of cancer patients contains a 
double amount, about 4000 trillion exosomes [57]. In noncancerous cells, exosome 
secretion was suggested to play a role in cellular homeostasis by removing harmful 
cytoplasmic DNA of normal cells and in preventing viral hijacking of host cells by 
excreting viral DNA from cells as shown by Takahashi et al. [58].
The plasma of cancer patients contains different types of exosomes, some 
released by normal cells and others released by cancerous cells, explaining the 
heterogeneity in size (30–150 nm) of the exosomal population [59]. Exosomes can 
be isolated from cancer patients’ plasma with a variety of methods [60]. They are 
based not only on classical techniques such as ultracentrifugation, but also on some 
modern ones such as size exclusion chromatography [61].
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Tumor cell-derived exosomes are able to promote inflammation and are able 
to compromise innate immunity by delivering different signals, which affect the 
proliferation, apoptosis, cytokine production, and reprogramming of T cells [62].
2.2 Ectosomes
Ectosomes are a heterogeneous vesicle population, ranging in diameter between 
100 and 1000 nm. Discovered in approximately the same time as exosomes, in 
1990s, ectosomes did not attract the same interest as the study of exosomes. While 
the interest in exosomes reached the maximum between 2008 and 2010, the ecto-
somes had its peak in 2012 [20, 63].
Ectosomes are known under different names, which might be misleading 
(Table 1), while ecto is a prefix that means outwardly, externally, and is therefore 
suggestive of their way of forming. The mechanism of formation of ectosomes 
differs greatly from that of exosomes, as well as their cargo molecules. Ectosome 
formation does not require exocytosis. Ectosomes are formed by direct outward 
Figure 1. 
Classification of EVs based on their diameter (expressed in nm) (A) or on their mechanism of biogenesis (B).
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budding of the plasma membrane in specialized microdomains of the plasma-
lemma, the phenomenon known as microvesicle shedding [29]. They are released 
both by cells in normal resting state and by cells upon stimulation. Ectosome fusion 
with the plasma membrane of a recipient cell is followed by changes in antigens, 
enzymes, and other proteins in a specific site of plasmalemma, while their content 
release into the cytoplasm can alter the recipients’ cell gene expression [64, 65]. 
Tumor-derived ectosomes were shown to have immunosuppressive properties by 
inducing the chemotaxis of granulocytes, lymphocytes, and monocytes due to 
several chemokines (e.g., particularly IL-8) transported in ectosomes [66].
Oncosomes are a particular type of ectosomes, excessively large, which can 
even reach 1000 nm, characteristic to advanced cancers. There is a confusion in 
the use of these terms in the literature and that is why we thought to treat onco-
somes as a particular category of ectosomes. The generic name of ectosomes can 
include oncosomes, while the name of oncosomes excludes ectosomes released 
from normal cells. Oncosomes content is adapted to serve cancer metabolism, 
so they will contain enzymes involved in glucose, glutamine, and amino acid 
metabolism. Furthermore, oncosomes are enriched in proteins, which have a 
Exosomes Ectosomes Apoptotic bodies
Size 30–100 nm 100–1000 nm 500–4000 nm
Sedimentation 
rate
100,000–120,000×g 16,000–20,000×g 5000–16,000×g
Biogenesis Endosomal pathway, 
accumulated within the 
multivesicular bodies, 
exocytosis [20]
Generated directly from 
the plasma membrane by 
shedding [21]
Cell fragmentation
Blebbing or zeiosis—
bulge of membrane by 
increasing the surface area 
through tearing [22]
Types of 
generation
Constitutive Regulated Regulated
Filtration 20–200 nm >200 nm >1000 nm
Intracellular 
storage
Yes No No
Marker proteins CD 9, CD63 and CD61, 
tetraspanins, HSP70, 
HSP90, Alix, Rab5a/b 
[23–25]
TyA and C1a, ARF6 and 
VCAMP3, β1 integrins, 
selectins, CD40, MMP, 
lineage markers, and 
ezrin [26–28]
Calreticulin, TSP and C3b, 
and histones [29, 30].
Content Proteins, cholesterol, 
ceramide, noncoding 
RNA, mRNA, miRNA, 
and cytosol [31]
Proteins, 
phosphatidylserine, 
cholesterol, mRNA, 
miRNA, and cytosol [31]
Proteins, 
phosphatidylserine, DNA, 
rRNA, and cytosol [18]
Organelles No No Yes
Alternative 
names
Prostasomes, 
tolerosomes, dexosomes, 
nanovesicles,
exosome-like vesicles, 
and others
[18, 32]
Nanoparticles, 
microparticles, 
microvesicles, shedding 
vesicles, shedding 
bodies, exovesicles, 
secretory vesicles, and 
oncosomes [18]
Apoptotic blebs [18]
Impact on the 
immune system
Immunostimulators Immunosuppressors Immunosuppressors
Table 1. 
Classification of EVs based on size and their biogenesis.
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role in cell migration, angiogenesis, and cancer progression and metastasis [28]. 
Oncosomes allow intercellular transfer of oncogenes, hence the motivation to 
be considered as existing biomarkers in the blood or plasma of patients for the 
detection of cancer [67].
2.3 Apoptotic bodies
Apoptotic bodies (ApoBDs) are the largest type of extracellular vesicles (typi-
cally 1–5 μm in diameter) visible during an apoptotic process. Kerr in 1972 proposed 
the term “apoptotic body” [68]. ApoBDs are released as blebs of cells undergoing 
apoptosis and consist of cytoplasm, organelles with or without a nuclear fragment. 
It has also been shown that ApoBDs can harbor proteins, lipids, DNA, rRNA, organ-
elles, and cytosol [18]; this is the reason why the disassembly of an apoptotic cell 
into ApoBDs can mediate intercellular communication and may contribute to the 
development of various disease states [69]. These bodies are then phagocytosed by 
macrophages or neoplastic cells and degraded within phagolysosomes. Their forma-
tion has been proposed to play an important role in the clearance of apoptotic cells 
by phagocytes. Different cell types can generate ApoBDs via different mechanisms 
[70]. These ApoBDs can be classified based on cell-type-specific surface markers 
and content. Jiang et al. showed that ApoBDs share the same surface markers as 
their cell of origin; this is the reason why apoptotic bodies are very different and can 
be divided into specific subclasses [70].
ApoBD occurs spontaneously in untreated malignant neoplasms, and is impli-
cated in both physiological involution and atrophy of various tissues and organs. 
Pathological settings include inflammation [71], autoimmunity [72–74], viral 
infection [75], and tumorigenesis because they participate in the horizontal transfer 
of oncogenes due to their nuclear material content from the dying cells [76].
3. Extracellular vesicles and tumor microenvironment
Tumor masses are composed of cancer cells and stromal cells, in which one 
include mesenchymal cells, fibroblasts and immune cells, and extracellular matrix 
(ECM) components. All these cells emit EVs and participate in the creation of a 
unique tumor nanoenvironment. EVs are capable of horizontal transfer of bioactive 
content to interact with cells in the tumor microenvironment. These interactions 
can include fusion of the EV with the plasmalemma of the recipient cell or endo-
cytosis of the EVs [77]. EVs represent the bidirectional way of interaction between 
stromal and cancer cells as a mean to exchange information and modify the tumor 
microenvironment. Therefore, the content of these vesicles is of great significance 
in the evolution of the cancer, since it was shown to modulate the complex signaling 
networks that facilitate tumor progression [78].
3.1 Nucleic acids
Circulating DNA can be found in free form or contained in EVs and is thought 
to be the future in cancer diagnosis and treatment monitoring. This will be pos-
sible because the DNA fragments contained in EVs are relatively intact (average 
15 kbp) by comparison with the circulating cell-free one (average 130 bp) due 
to the protection offered by the lipid bilayer [79]. Vagner et al. showed in a very 
recent study that the majority of the extracellular DNA is contained in large onco-
somes, rather than in exosomes, both in vitro and in the patients’ plasma and has 
all cancer-specific genomic alterations [80]. The majority of the DNA contained 
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in tumor-derived exosomes is double stranded and represent the whole genomic 
DNA, suggesting its usefulness in identifying mutations present in parental tumor 
cells, as it was indicated by Thakur et al. [81]. Wyatt et al. showed that cancer-
derived DNA is sufficient to identify the DNA alterations from metastatic tissue 
and is very important because it integrates somatic information from more than one 
metastatic lesion [82].
The presence of retrotransposons, cDNAs, and ncRNAs has also been reported 
in EVs and appears to be a unique feature of tumor cells [83]. Several studies 
reported a correlation between increased retrotransposon activity and tumorigen-
esis [84]. For example, LINE-1 hypomethylation in various human cancers was 
intensively studied since it is considered to be an early event in tumorigenesis and 
to be linked with the induction of proto-oncogenes [85]. Loss of LINE-1 methyla-
tion was found to associate with more aggressive progression of colorectal cancer 
[86]. Moreover, LINE-1 hypomethylation level can be considered as an important 
epigenetic process, which became a potential prognostic factor for ovarian multi-
step carcinogenesis [87].
miRNAs represent potential candidates responsible for influencing the tumor 
microenvironment; however, little is known about the mechanism by which they 
produce changes in the transcriptome of target cells [88].
3.2 Proteins
Proteins exported in EVs are signaling molecules that interfere in a whole series 
of processes such as cell metabolism, cell invasion and growth, angiogenesis, and 
mRNA processing [89]. Among these, it is worth mentioning that the epidermal 
growth factor receptor vIII (EGFRvIII), mutant Ras family members, or c-Met have 
been proposed as cancer biomarkers [90, 91]. Other proangiogenic regulators, such 
as VEGF and bFGF, are harbored in EVs shed from cancerous cells promoting new 
blood vessel formation [92].
Moreover, EVs also transfer proteases such as MMP-2, MMP-9, and MT1-MMP 
and become responsible for the partial degradation of the extracellular matrix [93]. 
The content is released in an acidic environment after the vesicle is stabilized in the 
extracellular matrix with the aid of β1 integrin adhesion molecules [94].
3.3 Lipids
Naturally, EVs also contain a lipid component, which consists of the main mem-
brane lipids: sphingomyelin, phosphatidylserine, and glycosphingolipids and cho-
lesterol, but they also carry polyunsaturated fatty acids PUFAs, mainly arachidonic 
acid and linoleic acid [95, 96]. Sphingomyelin, as a component of the EVS, was 
firstly reported by Kim et al. who described its angiogenic properties [97] . In addi-
tion, it has been shown that the lipid content of exosomes suppresses critical cancer 
survival pathways such as notch leading to cancer cell death of human pancreatic 
tumoral SOJ-6 cells [98]. Moreover, other important signaling mediators, such 
as prostaglandins, arachidonic acid, phospholipase A2, and phospholipase C and 
D, are also found in EVs [99]. The prostaglandins found in breast-cancer-derived 
exosomes, such as PGE2, are responsible for promoting tumor growth by inducing 
the release of pro-inflammatory cytokines such as IL-6 and VEGF, which induce 
the accumulation of myeloid-derived suppressor cells capable to differentiate into 
macrophages in the tumor microenvironment [100, 101]. PGE2 indeed makes the 
connection between cancer and macrophages and can promote tumorigenesis 
by enhancing the expression of programmed cell death protein ligand 1 (PD-L1) 
responsible for tumor escape from immune system during cancer progression [102].
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Cancer stem cells (CSCs) are held directly responsible to promote cancer initia-
tion and progression. Also, there are several studies showing their importance in 
therapy resistance, recurrence, and metastasis [103]. CSCs themselves do not exist 
as a static population, their stemness being supported by the mesenchymal stem 
cells, endothelial cells, fibroblasts, or immune cells by paracrine signaling [104]. 
For example, in breast cancer, the overexpression of the chemokines CXCL14 and 
CXCL12 in myoepithelial cells and myofibroblasts favors the metastasis [105]. 
Cancer-associated fibroblasts (CAF) release exosomes, which induce the stem-
ness of breast cancer cell lines, developing an aggressive cancer cell phenotype 
[106]. Also, the ECM molecules are relevant for breast cancer colonization, which 
contribute to the control of CSC. In this sense, tenascin C, a protein in the ECM, 
contributes in the formation of the stem niche by protecting CSC from immune sur-
veillance [107]. In breast cancer, high levels of tenascin C are associated with poor 
clinical outcome in breast cancer due to lung cancer metastasis [108].
4. Role of extracellular vesicles in tumorigenesis
The role of EVs in tumorigenesis was described in various types of cancer, 
including ovarian [109–111] and breast cancers [112, 113]. EVs undergo several 
alterations in tumorigenesis, including changes in their biogenesis, release rate and/
or protein content, incorporation of oncogenic and mutant macromolecules, medi-
ated release of genomic DNA, and uptake of tumoral cells [114]. The transfer of 
DNA between apoptotic tumoral cells and other cells is important in tumorigenesis. 
In vitro, it was shown that apoptotic bodies derived from cancer cells are respon-
sible for triggering the expression of oncogenes in fibroblasts due to the information 
contained in tumor-derived EVs [76].
In ovarian or breast cancer, investigating the content of EVs might give important 
informations on tumorigenesis. To detail, exosomes released by IGROV1 ovarian 
cancer cells (with high content of RNA-binding proteins, such as LIN28A or LIN28B), 
but not by OV420 ovarian cancer cells, were taken up by HEK293 cells, contributing 
to the tumor development [109]. Moreover, in hypoxia conditions, SKOV3 human 
epithelial ovarian cancer cells release exosomes with high content of miR-940 that 
stimulate the M2 macrophage phenotype, and in turn, M2 subtype macrophages 
stimulate the tumor cell migration and proliferation [111]. The majority of circulat-
ing miRNA, packed in EVs, can be used as biomarkers in ovarian cancer, but their use 
is not only limited for diagnosing the existence of the cancer, but also being reliable 
markers for monitoring the tumor histology, stage, or the patient outcome [110].
The content of EVs released from two human breast cancer cell lines, MCF-7 
(less invasive) and MDA-MB-231 (more invasive), was analyzed, and approxi-
mately, 270 proteins were identified [113]. In circulating EVs, epidermal growth 
factor-like repeats and discoidin I-like domains 3 (EDIL3) are the extracellular 
matrix (ECM) protein that was described to play a critical role in tumorigenesis 
by the activation of integrin-focal adhesion kinase (FAK) signaling cascade [113]. 
Breast-cancer-derived EVs (e.g., exosomes) present a cell-independent microRNA 
biogenesis from pre-miRNAs (like Dicer, AGO2, or TRBP) to mature miRNAs [112]. 
In particular, exosomes detected in the cells and sera of patients affected by breast 
cancer were shown to stimulate tumorigenesis in nontumoral epithelial cells by 
a Dicer-dependent mechanism [112]. It was also demonstrated that in the breast 
tumor microenvironment, there is a downregulation of the tumor suppressor p85α, 
which is clinically relevant in tumorigenesis, and the mechanism involves the loss of 
p85α expression in stromal fibroblasts promoting breast cancer progression by the 
epithelial-to-mesenchymal transition [111].
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5. Extracellular vesicles and metastatic niches
Tumor microenvironment was described to undergo series of molecular and 
cellular changes to form the metastatic-designated sites, called pre-metastatic niche 
[115, 116]. The formation of pre-metastatic niche requires the cross talk between 
primary tumor-derived components, and the microenvironment of the host stro-
mal components and of the tumor-mobilized bone-marrow-derived cells [117].
Interestingly, the role of EVs in metastatic niches can be exploited in novel 
therapeutic approaches. Indeed, technologies based on exosomes, separated from 
the ascitic fluid of ovarian cancer patients, embedded in a 3D scaffold metastatic 
trap, were successfully tested in murine models of ovarian metastasis in order to 
improve survival [118]. Numerous studies indicated that tumor-derived exosomes 
might play a role in promoting angiogenesis and modulation of the immune system  
[119, 120]. Moreover, exosomes derived from cancerous tumor are capable of 
remodeling the surrounding parenchyma, thus supporting tumor progression and 
the generation of the pre-metastatic niche [121, 122].
6. Role of extracellular vesicles in metastasis
EVs have been described to play an essential role in the local and distant 
communication between cancer cells and their environment and in contributing 
to the progression of metastasis [123]. Although the function of EVs in metastasis 
is not completely understood, studies show that miRNAs isolated from EVs are 
actively involved in complex metastatic processes, including local invasion, 
angiogenesis, immune modulation, metastatic niche preparation, colonization, 
and dormancy [123].
EVs play an essential role in the tumor metastasis by ensuring the cross talk 
between tumor and the adipose tissue, and obesity was described to influence 
the metastatic behavior of tumors, especially in melanoma, breast, and ovarian 
cancers [124].
In breast cancer, metastatic exosomes creating a facilitating local environment 
for metastasis was demonstrated, and annexin II contained in these exosomes 
contributes to this process by promoting angiogenesis [125].
7. Tumor-derived extracellular vesicles in ovarian cancer
Nawaz et al. have recently done an extensive review on the role of EVs in ovarian 
cancer and concluded that the gaining of new insights into these mechanisms would 
contribute to the identification of new biomarkers among the ovarian-cancer-
derived EVs and to the development of efficient EVs-based immunotherapies [126]. 
Proteomic analysis of exosomes derived from two human ovarian cancer cell lines 
(i.e., OVCAR-3 and IGROV1) indicated the presence of 2230 proteins, 1017 proteins 
being common for both cell lines, 380 proteins being newly reported compared to 
the ExoCarta database, and some of them being associated with tumorigenesis and 
metastasis and might represent promising biomarkers [127].
Additionally, matrix metalloproteinase-1 (MMP1) might be a very good bio-
marker for the ovarian cancer due to its overexpression in ascites-derived EVs in 
correlation with the degree of malignancy and the low prognosis for the ovarian 
cancer patients [128]. Moreover, the peritoneal dissemination of ovarian cancer is 
facilitated by malignant EVs containing MMP1 derived from the ascites of patients, 
and EVs were demonstrated to induce apoptosis in mesothelial cells [128].
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The mechanisms of drug resistance development also involve the release of 
EVs from ovarian cancer cells upon exposure to drug (i.e., cisplatin) and induce 
invasiveness [129].
8. Breast-cancer-derived extracellular vesicles
In breast cancer, EVs can play two essential roles “diagnosis biomarkers” or 
“therapeutic targets.” Thus, breast cancer induces the release of exosomes from 
salivary glands, being potential markers for early diagnosis [130]. Interestingly, 
EVs serve as a cargo not only for nucleic acids and proteins, but also for anticancer 
drugs. Considering the critical contribution of EVs in facilitating tumorigenesis, 
metastasis, and drug resistance [130], they could be considered as potential thera-
peutic targets in breast cancer.
Moreover, the analysis of EVs can help to distinguish the “degree of aggressive-
ness” in breast cancer. To detail, EVs derived from the aggressive human breast 
cancer MDA-MB-231 cell line, but not from the less invasive human breast cancer 
MCF-7 cell line, were demonstrated to induce platelet activation and aggregation 
by tissue factor-independent and tissue factor-dependent procoagulant activi-
ties [131]. EVs have been demonstrated to be involved in the cross talk between 
neighboring cancer cells and to transmit phenotypic aggressive traits from one cell 
to another. To date, EVs released by Hs578Ts(i)8 triple-negative breast cancer cells 
were able to increase the invasion, proliferation, and migration characteristics of 
Hs578T cells [132].
9. Extracellular vesicles as biomarkers—new diagnostic tools
In different body fluids, especially plasma and serum, EVs biomarkers have been 
detected with great clinical value in various types of cancer, Table 2.
The protein content of the EVs can be potentially used in the early detection 
of cancer as suggested in a pilot study by Smalley et al. [151]. The plasma levels of 
exosomal proteins represents an important biomarker that discriminates between 
ovarian cancer patients and normal ones, and their values correlate with the stage 
of the disease [119]. Among exosomal proteins, TGF-β1 and MAGE3/6 can be 
used as reliable biomarkers to discriminate between benign and malignant ovarian 
tumors, or to ascertain the efficacy of chemotherapy [119]. Although epithelial cell 
adhesion molecule (EpCAM) was demonstrated to promote epithelial-mesenchy-
mal transition in advanced stages of endometrial cancer [152], studies indicated 
that EpCAM is not a robust biomarker to classify exosomes derived from benign 
and malignant ovarian tumors [134] or to detect early stages of the pathology [153]. 
Besides EpCAM, several exosomal proteins were identified to be overexpressed 
in ovarian cancer, including proliferation cell nuclear antigen (PCNA), tubulin 
beta-3 chain (TUBB3), epidermal growth factor receptor (EGFR), apolipoprotein 
E (APOE), claudin 3 (CLDN3), fatty acid synthase (FASN), ERBB2, and L1CAM 
(CD171) [127]. Additionally, claudin-4, but not claudin-3, is a valuable biomarker 
in the peripheral blood of ovarian cancer patients with almost 98% specificity 
[133]. Exosomal proteins can also represent important biomarkers for the evalua-
tion of efficacy of therapies. Thus, annexin A3 can be employed for early detection 
of the resistance to platinum-based therapy in ovarian cancer patients [135, 136].
In breast cancer, several studies identified various exosomal miRNAs as poten-
tial biomarkers correlated with tumor malignancy degree and prognosis. Indeed, 
exosomal miR-21 and miR-1246 had higher levels in plasma of breast cancer 
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patients compared to control patients [138]. Additionally, high levels of exosomal 
miR-939 were associated with low outcome in patients with triple-negative breast 
cancer [139], and high levels of exosomal miR-373 were identified in triple- 
negative, estrogen–receptor- and progesterone-receptor-negative, breast cancer 
patients [58]. Moreover, an extensive proteomics analysis identified alpha1-
antitrypsin and haptoglobin precursors as novel biomarkers in the serum of patients 
with infiltrating ductal breast carcinomas [137].
The release of EVs has a calcium-dependent mechanism, and alterations in 
calcium signaling have been described in tumorigenesis, metastasis, or drug 
resistance in various types of cancer, including breast and ovarian cancers [154, 
155]. Therefore, more attention should be paid to the calcium-dependent signal-
ing cascades in different cancer stages in direct relationship with the cell-to-cell 
communication mechanisms of EVs in order to identify novel specific and reliable 
biomarkers.
10. Therapeutic roles of extracellular vesicles in cancer
EVs have a big potential for cancer therapy monitoring (Table 3). These are 
described as secreted lipid bilayer-enclosed lumens and are claimed to be valu-
able reservoirs of liquid biopsy biomarker [156]. EVs (mainly EVs-associated 
proteins and microRNAs) are proved to be the biomarkers in breast cancer 
diagnosis [157, 158].
Biomarkers of EVs Sample Types of cancer Reference
TGF-beta1, MAGE3/6, and 
Claudin-4
Plasma Ovarian cancer [119, 133]
EpCAM and annexin A3 Serum [134–136]
Alpha-1-antitrypsin and 
haptoglobin precursors
Serum Breast cancer [137]
miR-21, miR-939, miR-373, and 
miR-1246
Plasma [58, 138, 139]
miR-1290 and miR-375
Survivin, CD9+, CD63+, and 
alpha-1-antitrypsin
Plasma Prostate cancer [140–144]
IL-8 and TGF-beta mRNAs Plasma Glioma [60]
miR-21 CSF [145]
miR-1246, miR-4644, miR-3976, 
and miR-4306
CD44v6, Tspan8, EpCAM, and 
CD104
Serum Pancreatic cancer [146]
Alpha-1-antitrypsin, and histone 
H2B1K
Urine Urothelial carcinoma [147]
long coding RNA CRNDE-h Serum Lymph node and distant metastasis of 
colorectal cancer
[148]
miR-21 Plasma Esophageal cancer [149]
miR-19a l Serum Colorectal cancer [150]
Table 2. 
Biomarkers contained in EVs relevant in different types of cancer.
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11. Integrative overview
EVs play an essential role in cellular communication both in physiological and 
pathological conditions. In pathological conditions, EVs have been implicated in 
cancer, spreading of viruses or other pathogens, altered immune response, devel-
opment of neurodegenerative diseases, etc. In cancer, EVs ensure the cross talk 
between tumoral cells or between tumoral cells and nontumoral cells, and enable 
the development of multiple processes, including tumorigenesis, pre-metastatic 
niche formation, metastasis, and drug resistance. In ovarian and breast cancers, 
the involvement of EVs in all these processes of tumor evolution has been described 
and the analysis of EVs content is particularly useful for identifying biomark-
ers of the disease per se and, moreover, for the stage of the pathology evolution. 
However, there are still technical limitations for separation and/or analysis of EVs, 
and in clinical practice, the standardization of EVs-based reproductible protocols is 
required urgently. Considering the presence of EVs in such a variety of body fluids 
and tissues, an important conclusion is to consider EVs both as biomarkers and 
potential therapeutic targets (especially for immunotherapies) and to exploit them 
in the next future to improve the outcome of cancer patients.
Source of EVs Therapeutic effect Reference
Tumor peptide-loaded dendritic
cells-derived exosomes
Immunotherapy—because they suppress 
tumor growth
[159]
EVs from the rat pancreatic 
adenocarcinoma cell line BSp73ASML
Adjuvant therapy in immunotherapy [160]
Tumor antigen containing EVs Activates an antitumor response against 
OVA-transfected BL6–10 melanoma cells
[160]
EV vaccine derived from colorectal cancer 
(NB4 cell—a human acute promyelocytic 
leukemia cell line)
Activates CTLs through self-derived 
dendritic cell activation
[161]
EVs from self-derived dendritic cells Immunotherapy in cases of unresectable 
nonsmall-cell lung cancer
[162]
EVs from autologous self-derived dendritic 
cells
Metastatic melanoma patients [163]
EVs from ascites in combination with 
granulocyte macrophage colony-
stimulating factor
Immunotherapy in colorectal cancer [164]
miR-9 in mesenchymal stem cell-derived 
EVs
Chemosensitive in glioblastoma multiforme 
cells
[165]
iRGD-Exos-doxorubicin Suppressed breast tumor growth in an 
MDA-MB-231 tumor-bearing nude mouse 
model
[166]
Curcumin-primed EVs from a mouse brain 
endothelial cell line
Treating endothelial cell dysfunction during 
hyperhomocysteinemia in vitro
[167]
Table 3. 
EVs and their role in therapeutic approaches in cancer.
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